- Report
- March 2025
- 200 Pages
Global
From €4101EUR$4,490USD£3,507GBP
- Report
- May 2024
- 131 Pages
Global
From €5936EUR$6,499USD£5,076GBP
- Report
- May 2024
- 160 Pages
Global
From €4538EUR$4,969USD£3,881GBP
- Report
- August 2024
- 180 Pages
Global
From €2092EUR$2,290USD£1,789GBP
- Report
- April 2025
- 200 Pages
Global
From €4101EUR$4,490USD£3,507GBP
- Report
- March 2025
- 200 Pages
Global
From €4101EUR$4,490USD£3,507GBP
- Report
- March 2025
- 148 Pages
Global
From €2739EUR$2,999USD£2,342GBP
- Report
- April 2025
- 200 Pages
Global
From €7261EUR$7,950USD£6,209GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3425EUR$3,750USD£2,929GBP
- Report
- July 2024
- 138 Pages
Global
From €2283EUR$2,500USD£1,953GBP
- Report
- March 2025
- 18 Pages
Global
From €13696EUR$14,995USD£11,711GBP
- Report
- March 2025
- 118 Pages
Global
From €13696EUR$14,995USD£11,711GBP
- Report
- March 2022
- 75 Pages
Global
From €868EUR$950USD£742GBP
- Report
- November 2023
- 30 Pages
United States
From €2968EUR$3,250USD£2,538GBP
- Drug Pipelines
- July 2023
- 30 Pages
Global
From €2512EUR$2,750USD£2,148GBP
- Clinical Trials
- April 2024
- 180 Pages
Global
From €2740EUR$3,000USD£2,343GBP
- Report
- April 2023
- 165 Pages
Global
From €6850EUR$7,500USD£5,858GBP
- Report
- June 2022
- 148 Pages
Global
From €3608EUR$3,950USD£3,085GBP
- Report
- February 2020
- 253 Pages
Global
From €5708EUR$6,250USD£4,881GBP
- Report
- February 2024
- 180 Pages
Global
From €4538EUR$4,969USD£3,881GBP

The Major Depressive Disorder Drug market is a subset of the Mental Disorders Drugs market. It is composed of pharmaceuticals used to treat major depressive disorder, a mental health disorder characterized by persistent feelings of sadness, loss of interest, and fatigue. These drugs are typically prescribed by psychiatrists and other mental health professionals. Commonly prescribed drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs).
The Major Depressive Disorder Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, Eli Lilly, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and Novartis. Show Less Read more